Veeva (VEEV): A Record-Keeper Whose Own Books Are Under Audit

A high-quality life sciences software compounder has lost nearly half its value while the underlying business kept growing. What the numbers actually say at $162. Drug companies cannot be casual about their records. A trial result or a regulatory filing has to survive inspection by auditors and regulators years after it is created, and the software that stores all of it becomes very hard to pull out once it is in place. Veeva Systems (VEEV) builds that software. It is the industry cloud that drugmakers run their most sensitive workflows on, and for most of the last decade the market paid a clear premium for that position. Try our GNG AI Analyst, simply ask it “Do a stock analysis of VEEV or show a peer comparison for VEEV - https://www.gngresearch.com/ai-console Then the market changed its mind about the price, if not the business. Over the trailing twelve months the stock fell about 45% in the GNG dataset, and it now sits roughly 48% below its 52-week high of $310.50. The business, meanwhile, kept compounding revenue in the mid-teens and kept beating its own guidance. That gap between the filing and the stock chart is where the opportunity lives, and it is also the reason to stay disciplined. When a quality name drops this far, the honest first question is whether something actually broke. Sometimes a selloff is the market reading the books correctly before everyone else does. The right approach here is to do what an auditor would do, which is open the records and check whether the decline reflects real deterioration or a re-rating that ran ahead of the facts. A business built on being the system of record Veeva sells software that lives inside regulated life sciences. Its products span drug development, quality and manufacturing, clinical and regulatory work, commercial selling, and industry data, and the company is now layering AI agents on top of those systems. The strategic point is narrow on purpose. Veeva does not try to be general enterprise software that competes everywhere, and instead it owns workflows in one industry where compliance, validation, and the cost of switching vendors run unusually high. That focus shows up in the quality metrics. GNG shows a gross margin of 75.0%, an operating margin of 30.9%, and a net margin of 28.4%. The balance sheet carries roughly $1.88 billion in net cash with effectively no debt, a current ratio of 4.74, and an Altman Z-score above 11, which places it far from any financial stress. The Beneish M-score of -2.62 sits in the range associated with companies that are not massaging their numbers, and Veeva has cleared its earnings estimate in all eight of its last eight quarters. Switching costs are the moat. A drugmaker that runs its regulatory submissions and quality records inside one vendor's cloud does not casually rip that out, because doing so means re-validating systems that regulators depend on. That inertia is why Veeva has grown for years without buying revenue through heavy dilution, carrying a three-year share count growth rate of under 1%. A company that funds its own expansion instead of printing stock to pay for it tends to leave more value in the hands of the people who already own it.